| Literature DB >> 1426099 |
A Raza1, S Gezer, J Anderson, J Lykins, J Bennett, G Browman, J Goldberg, R Larson, R Vogler, H D Preisler.
Abstract
Pretherapy bone marrow (BM) aspirates of 143 patients with acute myeloid leukemia (AML) were incubated simultaneously with bromodeoxyuridine (BrdU) and tritiated cytosine arabinoside ([3H]Ara-C) to determine the labeling index (LI) and extent of [3H]Ara-C incorporation. Of 143 AML patients, 121 received high-dose Ara-C (HDAra-C) as a single agent for induction therapy (55 newly diagnosed, 66 in first relapse), whereas 22 received HDAra-C plus mAMSA. The data demonstrate that a subset of patients who will fail HDAra-C remission induction therapy because of drug-resistant disease can be prospectively identified on the basis of the low amount of Ara-C incorporated by their leukemia cells.Entities:
Mesh：
Substances：
Year: 1992 PMID： 1426099
Source DB: PubMed Journal: Exp Hematol ISSN： 0301-472X Impact factor: 3.084